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to malignant hypertensionAbdelrahman Gaber Salman, MD, FRCS ⇑AbstractPurpose: To evaluate the efficacy and safety of intravitreal bevacizumab (IVB) injection in persistent retinopathy secondary to
malignant hypertension (MHT).
Patients and methods: Single IVB injection of 1.25 mg/0.05 ml in 12 cases with persistent retinopathy secondary to MHT more than
one month after control of MHT with pre and post injection evaluation of best corrected visual acuity (BCVA) and anatomical out-
come up to sixth month and postinjection complications were evaluated.
Results: Progressive reductions in retinal hemorrhages, exudates, cotton-wool spots, and macular star were documented by pho-
tography, angiography, and central macular thickness (CMT) measured by optical coherence tomography (OCT) imaging.
Decreased macular edema was the most common finding. Improvement or stabilization of visual acuity was noted in all cases.
Conclusions: In addition to proper medical management of MHT, IVB injection is an effective and safe approach to treat persistent
retinopathy associated with MHT.
Abbreviations: MHT, malignant hypertension, IVB, intravitreal bevacizumab, BCVA, best corrected visual acuity, CMT, central
macular thickness, OCT, optical coherence tomographyKeywords: Malignant hypertension, Malignant hypertensive retinopathy
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Hypertension is ranked as the fourth greatest mortality risk
factor in the world. Acute hypertension of any cause can en-
ter an accelerated or malignant stage. Three different levels
of ocular fundus lesions are altered by arterial hypertension
including hypertensive retinopathy, choroidopathy, and optic
neuropathy.1
Keith et al. used the term malignant hypertension (MHT)
for the first time in the English literature in 1928 when they
reported on a series of patients with the presence of retinitis,
marked hyper-tension, and fairly adequate renal function.2
By 1939, Keith et al. had classified patients with hyperten-
sive retinopathy into 4 groups. They described the coursePeer review under responsibility
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Group I was restricted to minimal constriction of the reti-
nal arterioles with some tortuosity in mildly hypertensive pa-
tients. Group II included arteriovenous nipping, while group
III included hemorrhaging and exudates. Group IV included
papilledema.1,3
MHT is a clinical syndrome characterized by severe systolic
and diastolic hypertension, usually appearing progressively
over a period of several weeks to several months; it is often
associated with significant and progressive deterioration in
cardiac or renal function, and there is evidence of
encephalopathy.4Production and hosting by Elsevier
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the most useful for MHT; it now differentiates hypertensive
retinopathy on the basis of 2 grades of changes in the fundus,
fundus hypertonicus and fundus hypertonicus malignus.5 Pa-
tients diagnosed as having malignant hypertension have se-
vere hypertension with bilateral retinal hemorrhages and
exudates. Papilledema, unless florid, is an unreliable physical
sign and was of no additional prognostic importance in pa-
tients treated for hypertension who already had bilateral
hemorrhaging and exudates.6
Diastolic blood pressure is usually greater than 130 mm
Hg, but there is no absolute level above which MHT always
develops and below which it never occurs.7
Bevacizumab is a humanized monoclonal antibody that
competitively inhibits all isoforms of the VEGF-A family in
the extracellular space. While bevacizumab is currently ap-
proved by the Food and Drug Administration (FDA) for the
treatment of metastatic colorectal cancer, metastatic breast
cancer, and non-small cell lung cancer, it is widely used as
an off-label treatment for neovascular age-related macular
degeneration and retinal vascular disorders including retinal
vein occlusion and diabetic macular edema.8
Aim of our study was to evaluate efficacy and safety of
intravitreal bevacizumab (IVB) injection in persistent retinop-
athy secondary to MHT.Patients and methods
A prospective non randomized case series study was done
after acceptance of medical and ethical committees. All pa-
tients were informed that the therapy was off-label and the
relevant consent form was signed by them. The study wasTable 1. Clinical finding of patients with malignant hypertension retinopathy.
Patient (n) Gender Age in years Symptoms Past history BP in
1 Female 63 Blurred vision +ve 225/1
2 Male 45 Headache +ve 220/1
3 Male 54 Blurred vision +ve 230/1
4 Female 28 Headache ve 220/1
5 Female 27 Headache ve 240/1
6 Female 64 Blurred vision +ve 225/1
7 Male 49 Blurred vision +ve 220/1
8 Male 39 Blurred vision ve 235/1
9 Male 58 Headache ve 230/1
10 Female 27 Blurred vision ve 220/1
11 Female 52 Headache +ve 225/1
12 Male 54 Blurred vision +ve 220/1
Mean 42.9 226/1carried out by single IVB injection 1.25 mg/0.05 ml in both
eyes of 12 patients with persistent retinopathy secondary to
MHT more than one month after control of malignant hyper-
tension with pre and post injection evaluation of BCVA and
anatomical outcome up to the sixth month and postinjection
complications were evaluated.
All patients had visited an ophthalmologic clinic with the
chief complaint of acute blurred vision and headache or re-
ferred from internal medicine. Data of patients were included
when their color photographs of the fundus were judged to
indicate hypertensive retinopathy grade III or grade IV
according to Keith et al. classification3 of hypertensive
retinopathy.
There had to have been at least 2 successive high blood
pressure readings recorded in the chart during the period
when the symptoms occurred with diastolic blood pressure
of 120 mm Hg or more and systolic blood pressure of
220 mm Hg or more according to WHO definition of MHT
and we excluded patients with such diseases as diabetes mel-
litus, blood dyscrasia, and autoimmune and infectious dis-
eases which can mimic the fundus findings of MHT.
Intravitreal injection of 1.25 mg/0.05 ml bevacizumab
(Avastin, Genentech, South San Francisco, CA, USA) was gi-
ven after full asepsis in the operation room. Injection was
done in both eyes in 2 successive days. It was injected into
the vitreous cavity through the superotemporal quadrant,
4 mm from the limbus using 30-gauge needles with post
injection check of intraocular pressure. The patient was re-
viewed on the first postinjection day and at 1, 3, and 6 weeks
and followed up to 6 months after the last injection.
Statistics: SPSS 17 was used for statistical analysis and
(P < 0.05) was considered as statistically significant and
(P > 0.05) was considered as statistically insignificant.mm Hg Etiology Initial BCVA Log
MAR OD/OS
Final BCVA Log
MAR OD/OS
60 Essential hypertension 0.3/0.2
+0.5/+0.7
0.8/0.8
+0.1/+0.1
25 Renal hypertension 0.3/0.4
+0.5/+0.4
0.8/0.8
+0.1/+0.1
40 Renal hypertension 0.4/0.4
+0.4/+0.4
0.8/1.0
+0.1/0
30 Pheochromocvtoma 0.3/0.3
+0.5/+0.5
0.8/0.8
+0.1/+0.1
60 Preeclampsia 0.5/0.5
+0.3/+0.3
0.8/0.8
+0.1/+0.1
40 Renal hypertension 0.2/0.3
+0.7/+0.5
0.6/0.6
+0.2/+0.2
30 Essential hypertension 0.5/0.5
+0.3/+0.3
0.8/0.8
+0.1/+0.1
45 Renal hypertension 0.2/0.2
+0.7/+07
0.5/0.6
+0.3/+0.2
35 Essential hypertension 0.4/0.4
+0.4/+0.4
0.8/0.8
+0.1/+0.1
30 Preeclampsia 0.3/0.3
+0.5/+0.5
0.8/1.0
+0.1/0
30 Renal hypertension 0.2/0.2
+0.7/+0.7
0.8/0.6
+0.1/+0.2
25 Essential hypertension 0.3/0.4
+0.5/+0.4
0.8/1
+0.1/0
37 0.3/0.3
+0.5/+0.5
0.8/0.8
+0.1/+0.1
Figure 1. Typical malignant hypertensive persistent retinopathy grade IV in both eyes after one month. Disc swelling and hyperemia and a macular star
were revealed at the posterior pole and at the mid-periphery of the retina lower pictures showing the corresponding OCT.
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Twelve patients were included in our study (Table 1).
There were 5 males and 7 females. The study included 5 pa-
tients with no history of hypertension (group 1), while 7 pa-
tients had a known history of hypertension (group 2). The
ages ranged from 27 to 58 years in group 1 and 45 to
64 years in group 2. Systolic blood pressures ranged from
220 to 240 mm Hg in group 1 and 220 to 235 mm Hg in
group 2. Diastolic blood pressure ranged from 130 to
160 mm Hg in group 1 and 125 to 160 mm Hg in group 2. Pa-
tients in group 2 had a hypertension history with or without
receiving medication for it. They had been warned that they
had poorly controlled blood pressure, and it had been sug-
gested that they visit their internists for further treatment.
There were no significant differences in ages, or systolic
and diastolic blood pressures between the 2 groups.
(p > 0.05). Case 6 (group 2) developed renal failure 3 months
after MHT was diagnosed, although she was admitted for
intensive medical blood pressure control. Two patients in
group 2 experienced cerebral vascular accidents during the
period when MHT was diagnosed. No ocular or systemic
complications related to bevacizumab were noted during
the entire course of follow-up except subconjunctival hemor-
rhage in six eyes.
The initial BCVA is that at the time of presentation of the
patients to an ophthalmology clinic and the final BCVA is that
after one injection of IVB by the sixth month.
Clinically there were variations in fundus pictures between
retinal hemorrhages, exudate, cotton wool spots. All patients
have macular edema, macular star was present in 4 patients
and disc edema was present in 5 patients (Fig. 1up). In the fi-
nal visit sixth month post injection there was disappearance
of macular and disc edema, macular star, exudates, cotton
wool spots and hemorrhages except some hard exudatesor cholesterol deposits remained in 4 patients and some ret-
inal pigmentary changes in 3 patients (Fig. 2 up right and
left).
One month after the control of malignant hypertension
ten patients had persistent macular star in both eyes and four
patients showed persistent papilledema in both eyes. Six
weeks after IVB injection all macular star disappeared (statis-
tically highly significant p < 0.001) and two patients only
showed persistent disc swelling after 6 weeks of IVB injection
(statistically significant P < 0.05) (Fig. 2).
The mean pre injection Log MAR was +0.5 and mean post
injection after the 6 month was +0.1 which was statistically
significant (p < 0.5) (Fig. 3).
As regards the mean preinjection CMT in OCT the mean
was 350 lm in group 1 and 390 lm in group 2 and mean post
injection at the final visit after 6 months was 180 lm in group
1 and 210 lm in group 2.
For all patients the mean preinjection CMT was 375 lm
and the mean post injection after 6 months was 195 lmwhich
is statistically significant (P < 0.05) (Fig. 4).
As regards fluorescein leakage both groups 1 and 2 had
diffuse macular edema, alternate hyper and hypofluores-
cence in the posterior pole with disc leakage in 5 patients.
All patients showed absence of flourescine leakage at the
sixth month post injection.
Discussion
Our study included persistent hypertensive retinopathy
secondary to malignant hypertension with systolic blood
pressure more than 220 mm Hg and diastolic blood pressure
more than 220 mm Hg in which hypertension then became
controlled but with persistence of the retinopathy.
Fundus findings in systemic diseases such as systemic lu-
pus erythematosus, diabetes mellitus, and other collagen
Figure 2. Six months later after IVB injection and blood pressure was under control. The retinopathies showed nearly complete regression except for
mild disc swelling and lower pictures showing the corresponding OCT in the macula.
Figure 3. Comparison of Log MAR pre and 6 month post injection.
Figure 4. Comparison of CMT pre and 6 month post injection.
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nopathy. The overlapping findings in malignant hypertensive
retinopathy and in diabetic retinopathy can be confusing.MHR can cause optic nerve head swelling; and the optic
nerve head will appear hyperfluorescent with fluorescein
angiography.
The typical microaneurysms with FFA strongly suggest
diabetic retinopathy. The exudative retinopathy manifested
in diabetes tends to affect the deep capillaries, while hemor-
rhaging accumulates in the outer plexiform and inner nuclear
layer.9,10 However, the hemorrhaging due to hypertension
frequently arises from the superficial capillaries in the nerve
fiber layer. All of these changes distinguish hypertensive ret-
inopathy from that which is primarily diabetic. A systemic sur-
vey, including blood pressure and glycosylated hemoglobin
(HbA1c), can provide an important clinical differential diag-
nosis. That was why we excluded patients with systemic dis-
eases whose fundus manifestations might have caused
confusion.
We did not find significant relation between severity of
hypertension and degree of drop in initial visual acuity or ex-
tent of retinopathy and this may be due to our inclusion cri-
teria that all patients have blood pressure more than 220/
120 although proper medical control of MHT was essential
for both systemic and ocular improvement. This differs from
the study done by Browning et al.11 who found that the worst
visual prognosis was associated with the highest presented
blood pressure, the worst visual acuity at presentation, and
the longest duration of symptoms. It is likely that the visual
prognosis is affected by factors present at the time of presen-
tation, this may be due to lower categories of blood pres-
sure, So, early recognition is essential. In our group 1
patients, the visual prognosis was satisfactory when the
blood pressure and underlying disease were controlled.
Case 6 (group 2) developed renal failure 3 months after
MHT was diagnosed, although she was admitted for intensive
medical blood pressure control. Two patients in group 2
experienced cerebral vascular accidents during the period
when MHT was diagnosed.
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trol of malignant hypertension that ten patients had persis-
tent macular star in both eyes and four patients showed
persistent papilledema in both eyes. Six weeks after IVB
injection all macular star disappeared (statistically highly sig-
nificant p < 0.001) and two patients only showed persistent
disc swelling after 6 weeks of IVB injection (statistically signif-
icant P < 0.05).
It seems that there were more complications in group 2
patients. Maybe those patients had had a relatively longer
duration of high blood pressure, and that resulted in more
complications and related poorer prognoses.
In our study the mean pre injection Log MAR was +0.5 and
mean post injection after 6 month was +0.1 which was statis-
tically significant (p < 0.5)
As regards the mean preinjection CMT in OCT the mean
was 350 lm in group 1 and 390 lm in group 2 and mean post
injection at final visit after 6 months was 180 lm in group 1
and 210 lm in group 2.
For all the patients the mean preinjection CMT was
375 lm and the mean post injection after 6 months was
195 lm which is statistically significant (P < 0.05).
This improvement is in agreement with many studies
about improvement of retinopathy, vision, and CMT with
injection of intravitreal bevacizumab 1.25 mg/0.05 ml.12,13
Once hypertensive retinopathy is suspected in a patient
with acute vision decrease in both eyes, blood pressure
should be checked immediately. A detailed fundus examina-
tion and frequent blood pressure monitoring are mandatory.Conclusions
In addition to proper medical management of MHT, IVB
injection is an effective and safe approach to treat persistent
retinopathy associated with MHT.Source of support: Ophthalmology Department, Ain
Shams University.
Financial support: Fund of Ophthalmology Department,
Ain Shams University.References
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